Drs Michael S. Saag and Rajesh Gandhi discuss HIV and Antiretroviral Therapy Guidelines. When to begin treatment, which treatment to choose, and how to treat the whole person, not just the HIV.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986509). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

HIV Infection and AIDS https://emedicine.medscape.com/article/211316-overview

Zidovudine (Rx) https://reference.medscape.com/drug/retrovir-zdv-zidovudine-342639

ddI and d4T Plus Protease Inhibitors https://pubmed.ncbi.nlm.nih.gov/11364012/

HIV-Protease Inhibitors https://pubmed.ncbi.nlm.nih.gov/9562584/

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection https://pubmed.ncbi.nlm.nih.gov/26192873/

Early Symptomatic HIV Infection https://reference.medscape.com/article/211873-overview

IAS-USA https://www.iasusa.org/

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel https://pubmed.ncbi.nlm.nih.gov/36454551/

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs https://pubmed.ncbi.nlm.nih.gov/33572956/

Dolutegravir (Rx) https://reference.medscape.com/drug/tivicay-tivicay-pd-dolutegravir-999861

Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) https://www.medscape.com/viewarticle/941921_4

Dolutegravir/Lamivudine as a First-Line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34115650/

Tenofovir DF (Rx) https://reference.medscape.com/drug/viread-tenofovir-df-342633

Tenofovir AF (Rx) https://reference.medscape.com/drug/vemlidy-tenofovir-af-1000007

Abacavir (Rx) https://reference.medscape.com/drug/ziagen-abacavir-342600

HLA B 5701 Testing https://www.ncbi.nlm.nih.gov/books/NBK560797/

Dolutegravir/Rilpivirine (Rx) https://reference.medscape.com/drug/juluca-dolutegravir-rilpivirine-1000216

Efficacy and Safety of Dolutegravir-Rilpivirine for Maintenance of Virological Suppression in Adults With HIV-1: 100-Week Data From the Randomised, Open-Label, Phase 3 SWORD-1 and SWORD-2 Studies https://pubmed.ncbi.nlm.nih.gov/31307948/

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) https://clinicalinfo.hiv.gov/en/glossary/non-nucleoside-reverse-transcriptase-inhibitor-nnrti

Cabotegravir/Rilpivirine: The Last FDA-Approved Drug to Treat HIV https://pubmed.ncbi.nlm.nih.gov/35596583/

Anticipating and Managing Drug Interactions: Pharmacokinetics of Long-Acting HIV Treatment and Prevention Formulations https://www.medscape.com/viewarticle/986504

Mpox Vaccination Basics https://www.cdc.gov/poxvirus/mpox/vaccines/index.html

COVID-19 Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/summary-recommendations/

Mpox in People With Advanced HIV Infection: A Global Case Series https://pubmed.ncbi.nlm.nih.gov/36828001/

Information for Healthcare Providers: Tecovirimat (TPOXX) for Treatment of Mpox https://www.cdc.gov/poxvirus/mpox/clinicians/obtaining-tecovirimat.html

HIV and Opioid Use Disorder: Screening Tools, Chronic Pain Management, and Access to Care in the Outpatient Setting https://www.medscape.com/viewarticle/986506

Drs Michael S. Saag and David H. Spach discuss HIV and the nuances of primary care treatment, with a special focus on vaccines, including COVID, hepatitis, varicella zoster virus, and mpox.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986508). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

HIV Infection and AIDS https://emedicine.medscape.com/article/211316-overview

HIV and Immunizations https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-immunizations

HRSA Ryan White HIV/AIDS Program https://ryanwhite.hrsa.gov/about/parts-and-initiatives

Pneumococcal Vaccination https://www.cdc.gov/pneumococcal/vaccination.html

Incidence and Risk Factors for Invasive Pneumococcal Disease in HIV-Positive Individuals in the Era of Highly Active Antiretroviral Therapy https://pubmed.ncbi.nlm.nih.gov/30999829/

Pneumococcal 7-Valent Conjugate Vaccine https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pneumococcal-7-valent-conjugate-vaccine

Immunizations for Preventable Diseases in Adults and Adolescents Living With HIV https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/immunizations

Drug Database: Hepatitis B Vaccine https://clinicalinfo.hiv.gov/en/drugs/hepatitis-b-vaccine/patient

Interpretation of Hepatitis B Laboratory Results https://www.cdc.gov/hepatitis/statistics/surveillanceguidance/docs/viral-hepatitis-surveillance-table-3-1_508.pdf

Screening and Testing for Hepatitis B Virus infection: CDC Recommendations — United States, 2023 https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm?s_cid=rr7201a1_w

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Hepatitis B Virus Infection https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/hepatitis-b-0?view=full

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/what-start-initial-combination-regimens

Cabotegravir/Rilpivirine (Rx) Cabenuva (cabotegravir/rilpivirine) dosing, indications, interactions, adverse effects, and more https://reference.medscape.com/drug/cabenuva-cabotegravir-rilpivirine-4000156

Dolutegravir/Lamivudine as a First-Line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34115650/

Systematic Review and Meta-analysis of Immune Response of Double Dose of Hepatitis B Vaccination in HIV-Infected Patients https://pubmed.ncbi.nlm.nih.gov/32334887/

Heplisav-B® (HepB-CpG) Vaccine https://www.cdc.gov/vaccines/schedules/vacc-updates/heplisav-b.html

PreHevbrio: A New 3-Antigen Hepatitis B Vaccine for Adults https://pubmed.ncbi.nlm.nih.gov/35906803/

Hepatitis A Vaccine Inactivated (Rx) https://reference.medscape.com/drug/vaqta-havrix-hepatitis-a-vaccine-inactivated-343150

Hepatitis A/B Vaccine (Rx) https://reference.medscape.com/drug/twinrix-hepatitis-a-b-vaccine-343152

Zoster Vaccine Recombinant (Rx) https://reference.medscape.com/drug/shingrix-zoster-vaccine-recombinant-1000163

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 https://www.cdc.gov/mmwr/volumes/71/wr/mm7103a2.htm#:~:text=On%20October%2020%2C%202021%2C%20ACIP,for%20use%20in%20immunocompromised%20persons.

Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine) https://www.cdc.gov/flu/prevent/nasalspray.htm

MMR Vaccine https://www.ncbi.nlm.nih.gov/books/NBK554450/

Drs Michael S. Saag and Roger Bedimo discuss weight gain after starting antiretroviral therapy, including risk factors, long-term outcomes, and patients' well-being.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986507). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Weight Gain on INSTI-Based HIV Antiretrovirals https://www.medscape.com/viewarticle/916095#vp_2

Lipodystrophy in HIV Clinical Presentation https://emedicine.medscape.com/article/1082199-clinical

Protease Inhibitors' Metabolic Side Effects: Cholesterol, Triglycerides, Blood Sugar, and 'Crix Belly.' Interview With Lisa Capaldini, MD. Interview by John S. James https://pubmed.ncbi.nlm.nih.gov/11364559/

Reduced Survival After Serious Non-AIDS Complications https://www.medscape.com/viewarticle/721773

HIV Protease Inhibitor-Related Lipodystrophy Syndrome https://pubmed.ncbi.nlm.nih.gov/10860898/

Antiretroviral Therapy for HIV Infection https://emedicine.medscape.com/article/1533218-overview

Integrase Strand Transfer Inhibitor (INSTI) https://clinicalinfo.hiv.gov/en/glossary/integrase-strand-transfer-inhibitor-insti

Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) https://clinicalinfo.hiv.gov/en/glossary/non-nucleoside-reverse-transcriptase-inhibitor-nnrti

Strategies to Prevent Weight Gain Among Adults https://pubmed.ncbi.nlm.nih.gov/23638485/

Tenofovir Alafenamide (TAF) Clinical Pharmacology https://pubmed.ncbi.nlm.nih.gov/35146360/

Associations Between Integrase Strand-Transfer Inhibitors and Cardiovascular Disease in People Living With HIV: A Multicentre Prospective Study From the RESPOND Cohort Consortium https://pubmed.ncbi.nlm.nih.gov/35688166/

Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s https://pubmed.ncbi.nlm.nih.gov/34117756/

Is Tenofovir Disoproxil Fumarate Associated With Weight Loss? https://pubmed.ncbi.nlm.nih.gov/34848586/

Switching From Boosted PIs to Dolutegravir Decreases Soluble CD14 and Adiponectin in High Cardiovascular Risk People Living With HIV https://pubmed.ncbi.nlm.nih.gov/34120186/

Adiponectin: A Fat Cell Hormone That Promotes Insulin Sensitivity https://www.medscape.org/viewarticle/438373

Glucagon-like Peptide-1 Analogues: An Overview https://pubmed.ncbi.nlm.nih.gov/23869296/

Dolutegravir Plus Two Different Prodrugs of Tenofovir to Treat HIV https://pubmed.ncbi.nlm.nih.gov/31339677/

Weight and Metabolic Changes After Switching From Tenofovir Alafenamide (TAF)/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC+DTG and TDF/FTC/Efavirenz (EFV) to TDF/Lamivudine (3TC)/DTG https://pubmed.ncbi.nlm.nih.gov/36519389/

The ADVANCE Study: A Groundbreaking Trial to Evaluate a Candidate Universal Antiretroviral Regimen https://pubmed.ncbi.nlm.nih.gov/28538284/

Drs Michael S. Saag and Ellen F. Eaton discuss HIV and opioid use disorder, including opioid agonists for chronic pain management, tools for reducing mortality, and management in the outpatient setting.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986506). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Opioid Use Disorders in People Living With HIV/AIDS: A Review of Implications for Patient Outcomes, Drug Interactions, and Neurocognitive Disorders https://pubmed.ncbi.nlm.nih.gov/32932786/

Opioid Abuse https://emedicine.medscape.com/article/287790-overview

Opioids https://nida.nih.gov/research-topics/opioids

Drug Abuse Statistics https://drugabusestatistics.org/

Opioid Continuum of Care for Persons Living With HIV: The First 8 Months https://academic.oup.com/ofid/article/7/Supplement_1/S186/6058436

Medications to Treat Opioid Use Disorder Research Report: Overview https://nida.nih.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview

Buprenorphine https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/buprenorphine

Screening Tools https://ssc.jsi.com/resources/substance-use-screening-tools/list

The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) https://www.who.int/publications/i/item/978924159938-2

NIDA Quick Screen V1.0 https://nida.nih.gov/sites/default/files/pdf/nmassist.pdf

Rapid Opioid Dependence Screen (RODS) https://ssc.jsi.com/resources/substance-use-screening-tools/rapid-opioid-dependence-screen-rods

Removal of Data Waiver (X-Waiver) Requirement https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement

Naloxone DrugFacts https://nida.nih.gov/publications/drugfacts/naloxone

Endocarditis in Patients With Cocaine or Opioid Use Disorder Markedly Increased Between 2011 and 2022 https://nida.nih.gov/news-events/news-releases/2022/12/endocarditis-in-patients-with-cocaine-or-opioid-use-disorder-markedly-increased-between-2011-to-2022#:~:text=The%20incidence%20rate%20of%20infective,2022%2C%20a%20new%20study%20reports.

Buprenorphine Initiation Strategies for Opioid Use Disorder and Pain Management: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/35302671/

Low Barrier Medication for Opioid Use Disorder at a Federally Qualified Health Center: A Retrospective Cohort Study https://pubmed.ncbi.nlm.nih.gov/36335381/

Drs Michael S. Saag and Monica Gandhi discuss COVID-19 and the impact this pandemic has had on patients diagnosed with HIV, including vaccines, boosters, and patients who are older or have chronic comorbid conditions.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986505). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Coronavirus Disease 2019 (COVID-19) https://emedicine.medscape.com/article/2500114-overview

HIV Infection and AIDS https://emedicine.medscape.com/article/211316-overview

HIV https://www.who.int/news-room/fact-sheets/detail/hiv-aids

Molnupiravir, an Oral Antiviral Treatment for COVID-19 https://pubmed.ncbi.nlm.nih.gov/34159342/

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients https://pubmed.ncbi.nlm.nih.gov/34914868/

Molnupiravir for the Treatment of COVID-19 in Immunocompromised Participants: Efficacy, Safety, and Virology Results From the Phase 3 Randomized, Placebo-Controlled MOVe-OUT Trial https://pubmed.ncbi.nlm.nih.gov/36648627/

Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults With COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): An Open-Label, Platform-Adaptive Randomised Controlled Trial https://pubmed.ncbi.nlm.nih.gov/36566761/

Paxlovid https://pubmed.ncbi.nlm.nih.gov/35138785/

Protease Inhibitors as Promising Weapons Against COVID-19: Focus on Repurposing of Drugs Used to Treat HIV and HCV Infections https://pubmed.ncbi.nlm.nih.gov/34727849/

A Trial of Lopinavir-Ritonavir in Adults Hospitalized With Severe Covid-19 https://pubmed.ncbi.nlm.nih.gov/32187464/

Tenofovir Disoproxil Fumarate and Coronavirus Disease 2019 Outcomes in Men With HIV https://pubmed.ncbi.nlm.nih.gov/35848570/

Development of COVID-19 Vaccines–An Unanticipated Moon Shot Achieved at Warp Speed https://pubmed.ncbi.nlm.nih.gov/36689231/

Emerging Viral Diseases From a Vaccinology Perspective: Preparing for the Next Pandemic https://pubmed.ncbi.nlm.nih.gov/29199281/

A Bivalent Omicron-Containing Booster Vaccine Against Covid-19 https://pubmed.ncbi.nlm.nih.gov/36112399/

New Boosters Are Here! Who Should Receive Them and When? https://pubmed.ncbi.nlm.nih.gov/36354037/

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients https://pubmed.ncbi.nlm.nih.gov/35653428/

Nirmatrelvir Use and Severe Covid-19 Outcomes During the Omicron Surge https://pubmed.ncbi.nlm.nih.gov/36001529/

Drs Michael S. Saag and Charles W. Flexner discuss the mechanisms of drug-drug interactions and the promise and limitations of longer-acting HIV therapeutics for both treatment and prevention.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986504). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

HIV Infection and AIDS https://emedicine.medscape.com/article/211316-overview

Drug Interactions With Antiretroviral Therapy (ART) https://emedicine.medscape.com/article/2039809-overview

Common Drug Interactions With Protease Inhibitors https://emedicine.medscape.com/article/2041624-overview

HIV-Protease Inhibitors https://pubmed.ncbi.nlm.nih.gov/9562584/

The Role of Drug Metabolizing Enzymes in Clearance https://pubmed.ncbi.nlm.nih.gov/24392841/

AIDS Clinical Trials Group https://actgnetwork.org/

Ritonavir https://reference.medscape.com/drug/norvir-ritonavir-342627

The Cytochrome P450 Isoenzyme and Some New Opportunities for the Prediction of Negative Drug Interaction In Vivo https://pubmed.ncbi.nlm.nih.gov/29780235/

Boosting https://clinicalinfo.hiv.gov/en/glossary/boosting

Cytochrome p450 Structure, Function and Clinical Significance: A Review https://pubmed.ncbi.nlm.nih.gov/28124606/

Darunavir https://reference.medscape.com/drug/prezista-darunavir-342647

Atazanavir https://reference.medscape.com/drug/reyataz-atazanavir-342608

Tenofovir Disoproxil Fumarate https://clinicalinfo.hiv.gov/en/drugs/tenofovir-disoproxil-fumarate/patient

The Structure and Mechanism of Drug Transporters https://pubmed.ncbi.nlm.nih.gov/34272696/

Tenofovir Alafenamide (TAF) Clinical Pharmacology https://pubmed.ncbi.nlm.nih.gov/35146360/

Prodrugs for Improved Drug Delivery: Lessons Learned From Recently Developed and Marketed Products https://pubmed.ncbi.nlm.nih.gov/33137942/

Update on Drug-Drug Interaction at Organic Cation Transporters: Mechanisms, Clinical Impact, and Proposal for Advanced In Vitro Testing https://pubmed.ncbi.nlm.nih.gov/33896325/

The Role of Organic Anion Transporting Polypeptides in Drug Absorption, Distribution, Excretion and Drug-Drug Interactions https://pubmed.ncbi.nlm.nih.gov/27783531/

Creatinine Clearance https://pubmed.ncbi.nlm.nih.gov/31334948/

Dolutegravir https://reference.medscape.com/drug/tivicay-tivicay-pd-dolutegravir-999861

Cobicistat https://reference.medscape.com/drug/tybost-cobicistat-999845

Paxlovid https://pubmed.ncbi.nlm.nih.gov/35138785/

Interaction Between Ritonavir and Statins https://pubmed.ncbi.nlm.nih.gov/11959074/

COVID-19 Drug Interactions https://www.covid19-druginteractions.org/checker

Cabotegravir https://reference.medscape.com/drug/vocabria-apretude-cabotegravir-1000364

Lenacapavir https://reference.medscape.com/drug/sunlenca-lenacapavir-4000240

Inhibitors of the HIV-1 Capsid, a Target of Opportunity https://pubmed.ncbi.nlm.nih.gov/29782334/

Flip-Flop Pharmacokinetics--Delivering a Reversal of Disposition: Challenges and Opportunities During Drug Development https://pubmed.ncbi.nlm.nih.gov/21837267/

Polymeric Biomaterials for Medical Implants and Devices https://pubmed.ncbi.nlm.nih.gov/33465850/

Microneedle Arrays Combined With Nanomedicine Approaches for Transdermal Delivery of Therapeutics https://pubmed.ncbi.nlm.nih.gov/33419118/

Preexposure HIV Prophylaxis https://emedicine.medscape.com/article/2054869-overview

Drs Michael Saag and Judith Currier discuss options for long-acting HIV therapies, minimizing patient interactions with the healthcare system, and honoring patient preferences.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/963242). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

AIDS Clinical Trials Group (ACTG) https://www.niaid.nih.gov/research/aids-clinical-trials-group

Cabotegravir/Rilpivirine (Rx) https://reference.medscape.com/drug/cabenuva-cabotegravir-rilpivirine-4000156

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563641/

Antiretroviral Therapy for HIV Infection https://emedicine.medscape.com/article/1533218-overview

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/interactions-between-integrase-inhibitors-and-non-nucleoside

Initiation of Long-acting Cabotegravir Plus Rilpivirine as Direct-to-Injection or With an Oral Lead-in in Adults With HIV-1 Infection: Week 124 Results of the Open-Label Phase 3 FLAIR Study https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00184-3/fulltext

Lenacapavir (Pending FDA Approval) https://reference.medscape.com/drug/lenacapavir-4000240

Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir https://www.gilead.com/news-and-press/company-statements/gilead-and-merck-announce-temporary-pause-in-enrollment-for-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-islatravir-and-investigational-lenacapavir

Drug Database: Lenacapavir https://clinicalinfo.hiv.gov/en/drugs/lenacapavir/health-professional

Doravirine Prescribing Information https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_pi.pdf

A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults https://actgnetwork.org/studies/actg-a5357-a-study-of-long-acting-cabotegravir-plus-vrc01ls-to-maintain-viral-suppression-in-hiv-1-infected-adults/

Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV https://clinicaltrials.gov/ct2/show/NCT04334915?term=ACTG+5363&draw=2&rank=1

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189692/

Evusheld (Formerly AZD7442) Long-acting antibody Combination Authorised for Emergency Use in the US for Pre-exposure Prophylaxis (Prevention) of COVID-19 https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html

Drs Michael Saag and Glenn Treisman discuss methods of managing mental health and substance abuse in HIV patients.

Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963241). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Depression Prevalence, Antidepressant Treatment Status, and Association with Sustained HIV Viral Suppression Among Adults Living with HIV in Care in the United States, 2009-2014 https://link.springer.com/article/10.1007/s10461-019-02613-6

The Role of Dopamine in Inflammation-Associated Depression: Mechanisms and Therapeutic Implications https://link.springer.com/chapter/10.1007/7854_2016_13

Depression and Anxiety in Systemic Lupus Erythematosus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076116/pdf/medi-97-e11376.pdf

Substance Abuse Treatment in Persons with HIV/AIDS: Challenges in Managing Triple Diagnosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999248/pdf/nihms544493.pdf

Mesolimbic Pathway https://www.sciencedirect.com/topics/neuroscience/mesolimbic-pathway

Dopamine System Dysregulation in Major Depressive Disorders https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716179/pdf/pyx056.pdf

Drs Michael Saag and Michael Mugavero discuss the connection between antiretroviral therapy, retention, and care for patients with HIV.

Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963239). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

HIV Undetectable=Untransmittable (U=U), or Treatment as Prevention https://www.niaid.nih.gov/diseases-conditions/treatment-prevention#:~:text=U%3DU%20means%20that%20people,transmit%20the%20virus%20to%20others.

Ryan White Care Act https://ryanwhite.hrsa.gov/about/legislation

Beyond Binary Retention in HIV Care: Predictors of the Dynamic Processes of Patient Engagement, Disengagement, and Re-entry Into Care in a US Clinical Cohort https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136972/pdf/nihms-980338.pdf

Missed Visits and Mortality in Patients Establishing Initial Outpatient HIV Treatment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737584/

Beyond Core Indicators of Retention in HIV Care: Missed Clinic Visits Are Independently Associated With All-Cause Mortality https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215067/

Missed Office Visits and Risk of Mortality Among HIV-Infected Subjects in a Large Healthcare System in the United States https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739947/

Enhanced Personal Contact With HIV Patients Improves Retention in Primary Care: A Randomized Trial in 6 US HIV Clinics https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366591/pdf/ciu357.pdf

Drs Michael Saag and Constance Benson discuss antiretroviral therapy, maintenance, and switching.

Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963238). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals.

Resources

Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf

AIDS Clinical Trials Group https://actgnetwork.org/

Clarithromycin Therapy for Bacteremic Mycobacterium Avium Complex Disease https://www.acpjournals.org/doi/10.7326/0003-4819-121-12-199412150-00001?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

UC San Diego Medical Center https://healthlocations.ucsd.edu/san-diego/200-w.-arbor-drive-hospital

Highlights from the Ryan White Clinical Conference https://www.hiv.gov/blog/long-acting-injectables-hold-promise-maintaining-viral-suppression-and-preventing-hiv

Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492356/

Key Considerations and Recommendations for Early (Acute and Recent) HIV Infection https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/early-acute-and-recent-hiv-infection?view=full

Rising Rates of Recent Preexposure Prophylaxis Exposure Among Men Having Sex with Men Newly Diagnosed With HIV: Antiviral Resistance Patterns and Treatment Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876422/

Long-acting Cabotegravir Plus Rilpivirine for Treatment in Adults With HIV-1 Infection: 96-week Results of the Randomised, Open-Label, Phase 3 FLAIR Study https://linkinghub.elsevier.com/retrieve/pii/S2352-3018(20)30340-4